Literature DB >> 21038418

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.

Herbert Tilg1, Alexander R Moschen.   

Abstract

Whereas in most cases a fatty liver remains free of inflammation, 10%-20% of patients who have fatty liver develop inflammation and fibrosis (nonalcoholic steatohepatitis [NASH]). Inflammation may precede steatosis in certain instances. Therefore, NASH could reflect a disease where inflammation is followed by steatosis. In contrast, NASH subsequent to simple steatosis may be the consequence of a failure of antilipotoxic protection. In both situations, many parallel hits derived from the gut and/or the adipose tissue may promote liver inflammation. Endoplasmic reticulum stress and related signaling networks, (adipo)cytokines, and innate immunity are emerging as central pathways that regulate key features of NASH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21038418     DOI: 10.1002/hep.24001

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  736 in total

Review 1.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

2.  Metabolomic analysis of the effects of chronic arsenic exposure in a mouse model of diet-induced Fatty liver disease.

Authors:  Xiang Zhang; Walter H Watson; Xue Shi; Xiaoli Wei; Imhoi Koo; Robin H Schmidt; Xinmin Yin; Seong Ho Kim; Andrew Vaughn; Craig J McClain; Gavin E Arteel
Journal:  J Proteome Res       Date:  2013-12-17       Impact factor: 4.466

3.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 4.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

5.  Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis.

Authors:  Toshiaki Teratani; Kengo Tomita; Takahiro Suzuki; Hirotaka Furuhashi; Rie Irie; Makoto Nishikawa; Junji Yamamoto; Toshifumi Hibi; Soichiro Miura; Tohru Minamino; Yuichi Oike; Ryota Hokari; Takanori Kanai
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

6.  Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Enea Bonci; Lidia Marandola; Sara Romaggioli; Stefano Bascetta; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 7.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

9.  Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model.

Authors:  Toshiaki Okamoto; Masahiko Koda; Kennichi Miyoshi; Takumi Onoyama; Manabu Kishina; Tomomitsu Matono; Takaaki Sugihara; Keiko Hosho; Junichi Okano; Hajime Isomoto; Yoshikazu Murawaki
Journal:  World J Hepatol       Date:  2016-08-08

Review 10.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.